RxDoctor Payments Data

Charles Wilmer, MD

Interventional Cardiology · Atlanta, GANPI 1942205224

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,700 of the $36,705 with a category attached, or 78.2%. Johnson & Johnson accounts for 78.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $31,673 and has fallen 99.0% since, to $320 in 2025.

$36,705in general payments, 2019–2025

Across 125 payments — averaging $293.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$29K
  • E.r. Squibb & Sons, L.L.C.$7K
  • Novartis$530
  • Inspire Medical Systems, Inc.$168
  • Pfizer$96
  • Novo Nordisk$61
  • plus $185 from 6 others
$12in research payments, 2019–2025

Across 2 payments — averaging $6.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$12

What the payments were for

  • Consulting fees$5501%
  • Speaking & faculty fees$28,70078%
  • Travel & lodging$5,39815%
  • Food & beverage$1,9765%
  • Education$810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,705 in reported general payments places this provider in the 80th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$260,368
Medicare patients
3,005
Services billed
5,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$430,245
XareltoRivaroxaban182$241,155
JardianceEmpagliflozin30$44,351
EntrestoSacubitril/Valsartan25$29,421
Ezetimibe538$14,497
Rosuvastatin Calcium1,125$13,830
Flecainide Acetate180$11,432
VascepaIcosapent Ethyl26$9,795
Atorvastatin Calcium809$6,785
Amlodipine Besylate837$5,514
Dofetilide15$5,254
Metoprolol Succinate380$5,072
Losartan Potassium416$4,456
Metoprolol Tartrate673$3,881
Nebivolol Hcl49$3,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$96$430,245342 claims
Johnson & JohnsonXarelto$28,766$241,155182 claims
Boehringer IngelheimJardiance$29$44,35130 claims
NovartisEntresto$530$29,42125 claims
AstraZenecaCrestor$39$3,50313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →